BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15389515)

  • 1. Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase (hTERT) in epithelial cell lines.
    Chen F; Liu C; Lindvall C; Xu D; Ernberg I
    Int J Cancer; 2005 Jan; 113(2):284-9. PubMed ID: 15389515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling.
    Morrison JA; Raab-Traub N
    J Virol; 2005 Feb; 79(4):2375-82. PubMed ID: 15681438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway.
    Stewart S; Dawson CW; Takada K; Curnow J; Moody CA; Sixbey JW; Young LS
    Proc Natl Acad Sci U S A; 2004 Nov; 101(44):15730-5. PubMed ID: 15498875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus (EBV) LMP2A alters normal transcriptional regulation following B-cell receptor activation.
    Portis T; Longnecker R
    Virology; 2004 Jan; 318(2):524-33. PubMed ID: 14972521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.
    Terrin L; Dolcetti R; Corradini I; Indraccolo S; Dal Col J; Bertorelle R; Bonaldi L; Esposito G; De Rossi A
    Int J Cancer; 2007 Aug; 121(3):576-87. PubMed ID: 17417773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
    Pang MF; Lin KW; Peh SC
    Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency.
    Fruehling S; Swart R; Dolwick KM; Kremmer E; Longnecker R
    J Virol; 1998 Oct; 72(10):7796-806. PubMed ID: 9733815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
    Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
    Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
    Rechsteiner MP; Bernasconi M; Berger C; Nadal D
    Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
    Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
    J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
    Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
    Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation.
    Fukuda M; Kawaguchi Y
    J Virol; 2014 May; 88(9):5189-94. PubMed ID: 24554661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases.
    Ikeda M; Ikeda A; Longan LC; Longnecker R
    Virology; 2000 Mar; 268(1):178-91. PubMed ID: 10683340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the WW domain-interaction sites in the unstructured N-terminal domain of EBV LMP 2A.
    Seo MD; Park SJ; Kim HJ; Lee BJ
    FEBS Lett; 2007 Jan; 581(1):65-70. PubMed ID: 17174309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
    Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
    J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Epstein-Barr virus-encoded LMP1 and hTERT extends the life span and immortalizes primary cultures of nasopharyngeal epithelial cells.
    Yip YL; Tsang CM; Deng W; Cheung PY; Jin Y; Cheung AL; Lung ML; Tsao SW
    J Med Virol; 2010 Oct; 82(10):1711-23. PubMed ID: 20827769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through αv-integrin membrane translocation.
    Fotheringham JA; Coalson NE; Raab-Traub N
    J Virol; 2012 Oct; 86(19):10308-20. PubMed ID: 22837212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor.
    Ingham RJ; Raaijmakers J; Lim CS; Mbamalu G; Gish G; Chen F; Matskova L; Ernberg I; Winberg G; Pawson T
    J Biol Chem; 2005 Oct; 280(40):34133-42. PubMed ID: 16087662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity.
    Ducrest AL; Amacker M; Mathieu YD; Cuthbert AP; Trott DA; Newbold RF; Nabholz M; Lingner J
    Cancer Res; 2001 Oct; 61(20):7594-602. PubMed ID: 11606399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway.
    Fukuda M; Longnecker R
    J Virol; 2007 Sep; 81(17):9299-306. PubMed ID: 17582000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.